Reversing vascular dysfunction in type 1 diabetes

逆转 1 型糖尿病的血管功能障碍

• 批准号: 8925875
• 负责人: EUGENE Joseph BARRETT
• 金额: $ 60.83万
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-10 至 2018-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8925875
• 关键词: Adolescent; Adult; Affect; Age; Atherosclerosis; Biological Markers; Blood Vessels; Blood Volume; Cardiovascular Diseases; Cerebrum; Clinical Trials; Coronary; Discrimination; Disease; Disease Outcome; Employee Strikes; Exercise; Figs - dietary; Functional disorder; Gender; General Population; General Practices; Health; Hypertension; Hypoglycemia; Inflammation; Insulin; Insulin-Dependent Diabetes Mellitus; Intervention; Laboratories; Life Style; Lipids; Measurement; Measures; Mediating; Methods; Mineralocorticoid Receptor; Morbidity - disease rate; Multicenter Trials; Muscle function; Myocardial; Myocardium; Nitric Oxide; Patients; Perfusion; Peripheral; Peripheral arterial disease; Persons; Physiologic pulse; Population; Positioning Attribute; Prevalence; Property; Relaxation; Reporting; Resistance; Risk Factors; Skeletal Muscle; Structure; Testing; Training; Trees; Ultrasonography; Vascular Diseases; Vasodilation; Weight Gain; Woman; Work; arterial stiffness; basal insulin; base; blood glucose regulation; brachial artery; cardiovascular disorder risk; contrast enhanced; diabetic patient; diet and exercise; drug candidate; efficacy testing; endothelial dysfunction; eplerenone; fitness; glycemic control; healthy weight; high risk; improved; indexing; insulin sensitivity; men; middle age; mortality; novel strategies; prevent; programs; prospective; type I diabetic; vascular inflammation

 DESCRIPTION (provided by applicant): Large and small cerebral, coronary and peripheral arterial disease is the major cause of morbidity/mortality in type 1 diabetes (DM1). This begins early as indicated by evidence for arterial dysfunction in DM1 adolescents. Multicenter trials testing efficacy of vascular interventions to improve CVD outcomes in DM1 are lacking. Our general hypothesis is that DM1 impairs vascular function at multiple levels of the arterial vasculature and arterial vessels are resistant to insulin-induced vascular relaxation. We further hypothesize that mineralocorticoid receptor (MCR) blockade and/or enhanced fitness will improve DM1 arterial dysfunction. We will use non-invasive methods to assess arterial stiffness, (i.e. Pulse Wave Velocity and Augmentation Index) in conduit vessels, We will measure Flow-Mediated Dilation and Post-Ischemic Flow Velocity to assess endothelial function in conduit and resistance vessels and contrast-enhanced ultrasound to assess microvascular function. In Aim 1 we will measure pan-arterial vascular function in 18-50 y.o. DM1 and healthy age/gender matched controls in both the basal and insulin-stimulated state. Aim 1 will define whether the entire arterial tree is adversely affected by DM1 and whether vascular insulin sensitivity is impaired. It may also indicate which specific tests provide greatest discrimination between DM1 and controls. Duration of DM1, glycemic control, lipid profile, hypertension and evidence of inflammation will be co-variates in this analysis, In Aim 2 we will test whether basal or insulin-responsive pan-arterial function in 18-50 y.o. DM1 responds to a 12 week lifestyle (fitness training) or pharmacologic (eplerenone) intervention or combined fitness plus eplerenone. Fitness and eplerenone have beneficial vascular effects in other populations. If these hypotheses prove correct, they will indicate: A) whether in the basal or insulin treated state ther is pan-arterial vascular dysfunction or is it restricted to one or another vascular level; B) whethr insulin's vascular action (or resistance) contributes to the linkage between DM 1 and CVD; C) a compelling rationale for further emphasizing diet/exercise interventions or early pharmacologic interventions to avoid CVD. In addition, the approach used here may suggest that early assessment pan-arterial function can afford a platform to improve selection of drug candidates for later hard endpoint clinical trials in DM1.

 描述（由申请方提供）：大、小脑、冠状动脉和外周动脉疾病是1型糖尿病（DM 1）发病/死亡的主要原因。DM 1型青少年动脉功能障碍的证据表明，这种情况很早就开始了。缺乏多中心试验来测试血管介入治疗改善DM 1患者CVD结局的疗效。我们的一般假设是，DM 1在动脉血管系统的多个水平上损害血管功能，并且动脉血管对胰岛素诱导的血管舒张具有抗性。我们进一步假设盐皮质激素受体（MCR）阻断和/或增强健身将改善DM 1动脉功能障碍。我们将使用非侵入性方法评估管道血管中的动脉硬度（即脉搏波速度和增强指数），我们将测量血流介导的扩张和缺血后血流速度以评估管道和阻力血管中的内皮功能，并使用造影剂增强超声评估微血管功能。在目标1中，我们将测量18-50岁的全动脉血管功能。DM 1和健康年龄/性别匹配的对照在基础和胰岛素刺激状态。目标1将定义整个动脉树是否受到DM 1的不利影响以及血管胰岛素敏感性是否受损。它还可以表明哪些特定的测试提供了DM 1和控制之间的最大区别。DM 1的持续时间、血糖控制、血脂谱、高血压和炎症证据将是该分析中的协变量。在目标2中，我们将测试18-50岁的糖尿病患者的基础或胰岛素反应性泛动脉功能是否与糖尿病相关。DM 1对12周的生活方式（健身训练）或药物（依普利酮）干预或健身加依普利酮的组合有反应。健身和依普利酮在其他人群中具有有益的血管效应。如果这些假设被证明是正确的，它们将表明：A）在基础状态或胰岛素治疗状态下，是否存在泛动脉血管功能障碍，或者它是否局限于一个或另一个血管水平; B）胰岛素的血管作用（或阻力）是否有助于DM 1和CVD之间的联系; C）进一步强调饮食/运动干预或早期药理学干预以避免CVD的令人信服的理由。此外，本文使用的方法可能表明，早期评估全动脉功能可以提供一个平台，以改善候选药物的选择，用于DM 1的后期硬终点临床试验。